HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Schwannomatosis

A neurofibromatosis characterized by multiple cutaneous neurilemmomas and spinal schwannomas, without ACOUSTIC NEUROMAS or other signs of NEUROFIBROMATOSIS I (OMIM: 162200) or NEUROFIBROMATOSIS II (OMIM: 101000); neurilemmomas consist of SCHWANN CELLS. Some patients may develop MENINGIOMAS. Germline mutations in the SMARCB1 gene and somatic mutations in the NF2 gene have been identified. OMIM: 162091
Also Known As:
Neurilemmomatosis, congenital cutaneous; Schwannomatosis 1
Networked: 83 relevant articles (3 outcomes, 11 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neurofibromatoses (Neurofibromatosis)
2. Pain (Aches)
3. Neurofibromatosis 1 (Neurofibromatosis Type I)
4. Neoplasms (Cancer)
5. Neurofibromatosis 2 (Neurofibromatosis Type II)

Experts

1. Evans, D Gareth: 10 articles (10/2022 - 03/2012)
2. Plotkin, Scott R: 10 articles (01/2022 - 12/2012)
3. Blakeley, Jaishri O: 8 articles (01/2022 - 03/2013)
4. Smith, Miriam J: 7 articles (10/2022 - 05/2012)
5. Giovannini, Marco: 5 articles (01/2022 - 03/2013)
6. Legius, Eric: 5 articles (01/2022 - 03/2014)
7. Stemmer-Rachamimov, Anat: 5 articles (01/2022 - 03/2012)
8. Bowers, Naomi L: 4 articles (10/2022 - 05/2012)
9. Wallace, Andrew J: 4 articles (10/2022 - 12/2005)
10. Ferner, Rosalie: 4 articles (01/2022 - 03/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Schwannomatosis:
1. Bevacizumab (Avastin)FDA Link
2. tanezumabIBA
3. DNA (Deoxyribonucleic Acid)IBA
4. Biomarkers (Surrogate Marker)IBA
5. Uvitex SWN (SWN)IBA
6. AntibodiesIBA
7. Neurofilament ProteinsIBA
8. Protons (Proton)IBA
9. S100 Proteins (S 100 Protein)IBA
10. Drug CombinationsIBA

Therapies and Procedures

1. Therapeutics
2. Radiotherapy
3. Cochlear Implants (Cochlear Implant)
4. Off-Label Use
5. Auditory Brain Stem Implants (Auditory Brainstem Implants)